Digoxin: Cardiac Glycoside for Heart Failure Research & CHIKV Inhibition

Executive Summary: Digoxin is a high-purity cardiac glycoside provided by APExBIO, acting as a potent Na⁺/K⁺-ATPase pump inhibitor for cardiovascular and antiviral research (APExBIO Digoxin). It increases intracellular sodium and calcium, enhancing cardiac contractility and has demonstrated dose-dependent inhibition of chikungunya virus (CHIKV) in multiple human cell lines. Digoxin is soluble at ≥33.25 mg/mL in DMSO, insoluble in water and ethanol, and should be stored as a solid at room temperature. Its in vivo efficacy is validated in canine models of heart failure, where intravenous administration improves cardiac output. All claims in this article are referenced with peer-reviewed or primary vendor documentation.

Biological Rationale

Digoxin is a member of the cardiac glycoside class, molecules that modulate cardiac function by inhibiting the Na⁺/K⁺-ATPase pump. This mechanism underpins both its classical use in heart failure research and emerging roles in virology, particularly against CHIKV. The Na⁺/K⁺-ATPase is essential for maintaining cellular ion gradients, electrical excitability, and contractile function in cardiac tissue (see prior review). Digoxin’s action leads to increased intracellular sodium, which subsequently raises intracellular calcium via the Na⁺/Ca²⁺ exchanger—a critical pathway for modulating myocardial contractility. Recent studies also implicate Na⁺/K⁺-ATPase inhibition in pathways relevant to viral entry and replication, providing a rationale for its antiviral investigation.

Mechanism of Action of Digoxin

Digoxin binds to the extracellular domain of the Na⁺/K⁺-ATPase pump, inhibiting active transport of sodium and potassium ions across the plasma membrane (Digoxin product page). This inhibition results in elevated intracellular Na⁺ concentration. The increased sodium impedes the normal function of the Na⁺/Ca²⁺ exchanger, causing accumulation of intracellular Ca²⁺. Elevated intracellular calcium enhances cardiac muscle contractility (positive inotropism), which is essential in the context of congestive heart failure research. In virology, this ionic disturbance disrupts processes exploited by viruses for entry or replication, notably observed with chikungunya virus infection in human and primate cell lines (DOI:10.1016/j.biopha.2025.118665).

Evidence & Benchmarks

• Digoxin exhibits >98.6% purity as verified by HPLC and NMR (see APExBIO QC documentation: product page).
• Demonstrates potent inhibition of Na⁺/K⁺-ATPase pump activity in vitro at nanomolar concentrations (Digoxin: Cardiac Glycoside for Heart Failure Research & Antiviral Applications).
• In U-2 OS, primary human synovial fibroblasts, and Vero cells, Digoxin impairs chikungunya virus (CHIKV) infection in a dose-dependent manner from 0.01 to 10 μM (DOI:10.1016/j.biopha.2025.118665).
• Animal studies (canine congestive heart failure) show that intravenous Digoxin (1–1.2 mg) increases cardiac output and reduces right atrial pressure (New Frontiers in Cardiac and Antiviral Utility).
• Solubility profile: ≥33.25 mg/mL in DMSO, insoluble in water/ethanol; solid form stable at room temperature (APExBIO).

Applications, Limits & Misconceptions

Digoxin’s validated mechanisms enable its use in research on cardiac contractility modulation, arrhythmia models, heart failure, and as an antiviral agent against CHIKV. These applications are supported by reproducible, dose-dependent effects in both cell-based and animal models. For in vitro use, Digoxin’s solubility in DMSO enables high-concentration stock solutions (≥33.25 mg/mL), facilitating precise dosing across a range of assay conditions.

This article extends prior reviews by focusing on atomic, machine-readable claims and by explicitly benchmarking Digoxin for both cardiovascular and virology applications, complementing broader scenario-driven guidance in this APExBIO-focused article.

Common Pitfalls or Misconceptions

• Not suitable for water/ethanol-based stock solutions: Digoxin is insoluble in water and ethanol; use DMSO for experimental stocks (APExBIO).
• Not recommended for long-term solution storage: Prepare fresh solutions for each experiment as stability in solution is not guaranteed.
• Species-specific responses: Efficacy and toxicity in humans may not extrapolate directly from canine or cell models.
• Non-specific antiviral claims: While effective against CHIKV in vitro, antiviral effects have not been generalized to unrelated viral families.
• Not a replacement for primary anti-arrhythmic drugs in clinical protocols: Digoxin’s role is as a research tool, not a front-line clinical agent for arrhythmia management (Gold-standard Na+/K+ ATPase inhibitor review).

Workflow Integration & Parameters

For cell-based assays, Digoxin is typically reconstituted in DMSO at ≥33.25 mg/mL and diluted to working concentrations between 0.01 and 10 μM. For animal models, intravenous dosing in canine heart failure studies uses 1–1.2 mg per animal. Quality control is ensured by batch-specific HPLC and NMR data supplied by APExBIO. Storage as a solid at room temperature preserves integrity; solutions should be made fresh prior to each use. For full guidance on troubleshooting and workflow optimization, see Digoxin: Cardiac Glycoside for Heart Failure & Antiviral Applications—this article adds explicit integration parameters and QC benchmarks not detailed in previous reviews.

Conclusion & Outlook

Digoxin remains a cornerstone research tool for dissecting cardiac contractility, arrhythmia mechanisms, and antiviral strategies against CHIKV. Its well-characterized mode of action, reproducible solubility, and batch-specific QC make it a reliable choice for preclinical workflows. As new applications in virology and signal transduction emerge, Digoxin’s robust documentation and experimental flexibility will continue to drive innovation in both cardiovascular and infectious disease research. For product details and ordering, see the APExBIO Digoxin B7684 kit.